RxDoctor Payments Data

Thomas Flautt, DO

Clinical Cardiac Electrophysiology · Houston, TXNPI 1215342241

Payments from drug & device makers

$74,283in general payments, 2019–2025

Across 952 payments — averaging $78.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$32K
  • Biosense Webster, Inc.$20K
  • Abbott$7K
  • Boston Scientific$5K
  • Biotronik Inc.$3K
  • Pfizer$867
  • plus $6K from 39 others

What the payments were for

  • Consulting fees$10,19714%
  • Grants$22,64230%
  • Travel & lodging$15,16420%
  • Food & beverage$25,77135%
  • Education$5091%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$74,283 in reported general payments places this provider in the 65th percentile of 233 clinical cardiac electrophysiology providers in Texas.

See all clinical cardiac electrophysiology providers in Texas

Medicare billing

Part B allowed, 2024
$610,935
Medicare patients
1,757
Services billed
8,627

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban263$176,190
JardianceEmpagliflozin66$40,215
XareltoRivaroxaban56$34,264
FarxigaDapagliflozin Propanediol43$27,144
MounjaroTirzepatide12$18,399
Praluent PenAlirocumab17$8,381
Flecainide Acetate282$6,086
Sucralfate45$5,307
Metoprolol Succinate277$1,872
Amiodarone Hcl187$1,623
SotalolSotalol Hcl137$1,220
Propafenone Hcl13$540
Minocycline Hcl149$523
Pantoprazole Sodium101$497
Bisoprolol Fumarate35$485

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$867$176,190263 claims
Boehringer IngelheimJardiance$381$40,21566 claims
Johnson & JohnsonXarelto$270$34,26456 claims
AstraZenecaFarxiga$279$27,14443 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 233 clinical cardiac electrophysiology providers in Texas.

Other clinical cardiac electrophysiology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →